Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study.
Bernardo Cortese, Andrea Micheli, Andrea Picchi...
https://pubmed.ncbi.nlm.nih.gov/20659948/Actively Recruiting
Led by Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS · Updated on 2025-12-03
140
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are comparing two types of drug-coated balloons, Selution sirolimus coated balloon and SeQuent Please Neo paclitaxel coated balloon, for treating new coronary artery lesions in medium-small vessels sized between greater than 2.00 mm and 3.00 mm. The study aims to evaluate differences in artery diameter improvement Net Gain and blood flow measurement Fractional Flow Reserve at 12 months after treatment. This multicenter, randomized study focuses on patients with small vessel coronary artery disease and stable or stabilized heart conditions. Participants will receive angioplasty using one of the two drug-coated balloons after successful lesion preparation. Patients are randomized 11 to either the sirolimus or paclitaxel balloon groups, stratified by balloon length less than 30 mm or 30 mm and longer. Other non-study lesions may be treated with standard devices if needed. Follow-ups include phone calls at 1 and 6 months, with an angiographic and blood flow assessment at 12 months at the original treatment center. During the study, participants will undergo imaging assessments before and after the procedure and at one year to measure artery narrowing and blood flow. Measurements include quantitative coronary angiography and fractional flow reserve. Dual antiplatelet therapy is required for at least one month post-procedure, followed by aspirin alone indefinitely. Researchers will monitor device and procedure success, heart-related events, and vessel health throughout the 12-month period.
CONDITIONS
SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
M
Marina MCS Cornacchia Schenetti
R
Riccardo RF Falzone
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure with follow-up visits up to 12 months
Participants receive PCI treatment with either a sirolimus-eluting balloon or a paclitaxel-eluting balloon to treat a coronary artery lesion in a small vessel.
1 procedure visit (in-person)
Duration - 12 months post-procedure
Participants are followed by phone call at 1 and 6 months post-procedure and return for an angiographic follow-up visit at 12 months to assess outcomes.
2 phone call visits and 1 angiographic visit (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bernardo Cortese, Andrea Micheli, Andrea Picchi...
https://pubmed.ncbi.nlm.nih.gov/20659948/Sho Torii, Kazuyuki Yahagi, Hiroyoshi Mori...
https://pubmed.ncbi.nlm.nih.gov/29754850/Eun-Seok Shin, Soe Hee Ann, Gillian Balbir Singh...
https://pubmed.ncbi.nlm.nih.gov/26423017/Shuzou Tanimoto, Joost Daemen, Keiichi Tsuchida...
https://pubmed.ncbi.nlm.nih.gov/17139687/Hector M Garcia-Garcia, Eugène P McFadden, Andrew Farb...
https://pubmed.ncbi.nlm.nih.gov/29891620/William F Fearon, Leora B Balsam, H M Omar Farouque...
https://pubmed.ncbi.nlm.nih.gov/12821539/Roisin Colleran, Yukinori Harada, Sebastian Kufner...
https://pubmed.ncbi.nlm.nih.gov/28134126/Sho Torii, Hiroyuki Jinnouchi, Atsushi Sakamoto...
https://pubmed.ncbi.nlm.nih.gov/30527654/Mario Togni, Stéphanie Eber, Jeannette Widmer...
https://pubmed.ncbi.nlm.nih.gov/17868802/Ryoko Nakamura, Sho Torii, Tsukasa Kato...
https://pubmed.ncbi.nlm.nih.gov/35780056/Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Lead Sponsor